Switch theme
Sign up to access all valuation multiples
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
2013
923
LTM Revenue $347M
LTM EBITDA -$148M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Twist Bioscience has a last 12-month revenue of $347M and a last 12-month EBITDA of -$148M.
In the most recent fiscal year, Twist Bioscience achieved revenue of $313M and an EBITDA of -$177M.
Twist Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Twist Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $245M | $313M | XXX | XXX | XXX |
| Gross Profit | $84.2M | $89.7M | XXX | XXX | XXX |
| Gross Margin | 34% | 29% | XXX | XXX | XXX |
| EBITDA | -$174M | -$177M | XXX | XXX | XXX |
| EBITDA Margin | -71% | -56% | XXX | XXX | XXX |
| Net Profit | -$218M | -$205M | XXX | XXX | XXX |
| Net Margin | -89% | -65% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Twist Bioscience's stock price is $40.
Twist Bioscience has current market cap of $2.4B, and EV of $2.2B.
See Twist Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2.4B | XXX | XXX | XXX | XXX | $-2.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Twist Bioscience has market cap of $2.4B and EV of $2.2B.
Twist Bioscience's trades at 6.3x LTM EV/Revenue multiple, and -14.8x LTM EBITDA.
Analysts estimate Twist Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Twist Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | -13.7x | XXX | XXX | XXX |
| P/E | -12.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -32.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTwist Bioscience's NTM/LTM revenue growth is 19%
Twist Bioscience's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Twist Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Twist Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Twist Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -49% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 99% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Twist Bioscience acquired XXX companies to date.
Last acquisition by Twist Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Twist Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Twist Bioscience founded? | Twist Bioscience was founded in 2013. |
| Where is Twist Bioscience headquartered? | Twist Bioscience is headquartered in United States of America. |
| How many employees does Twist Bioscience have? | As of today, Twist Bioscience has 923 employees. |
| Who is the CEO of Twist Bioscience? | Twist Bioscience's CEO is Dr. Emily M. Leproust, PhD. |
| Is Twist Bioscience publicy listed? | Yes, Twist Bioscience is a public company listed on NAS. |
| What is the stock symbol of Twist Bioscience? | Twist Bioscience trades under TWST ticker. |
| When did Twist Bioscience go public? | Twist Bioscience went public in 2018. |
| Who are competitors of Twist Bioscience? | Similar companies to Twist Bioscience include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Twist Bioscience? | Twist Bioscience's current market cap is $2.4B |
| What is the current revenue of Twist Bioscience? | Twist Bioscience's last 12-month revenue is $347M. |
| What is the current EBITDA of Twist Bioscience? | Twist Bioscience's last 12-month EBITDA is -$148M. |
| What is the current EV/Revenue multiple of Twist Bioscience? | Current revenue multiple of Twist Bioscience is 6.3x. |
| What is the current EV/EBITDA multiple of Twist Bioscience? | Current EBITDA multiple of Twist Bioscience is -14.8x. |
| What is the current revenue growth of Twist Bioscience? | Twist Bioscience revenue growth between 2023 and 2024 was 28%. |
| Is Twist Bioscience profitable? | Yes, Twist Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
